Co Diagnostics Company Insiders
CODX Stock | USD 0.94 0.01 1.08% |
Co Diagnostics employs about 155 people. The company is managed by 14 executives with a total tenure of roughly 23 years, averaging almost 1.0 years of service per executive, having 11.07 employees per reported executive. Break down of Co Diagnostics' management performance can provide insight into the company performance.
Dwight Egan Chairman Chairman of the Board and Presidentident, CEO |
CODX |
Co Diagnostics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2761) % which means that it has lost $0.2761 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5057) %, meaning that it created substantial loss on money invested by shareholders. Co Diagnostics' management efficiency ratios could be used to measure how well Co Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to rise to -0.45 in 2024. At this time, Co Diagnostics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 34.8 M in 2024, whereas Total Assets are likely to drop slightly above 50.6 M in 2024.Common Stock Shares Outstanding is likely to drop to about 22.2 M in 2024. Net Loss is likely to rise to about (15.6 M) in 2024
Co Diagnostics Workforce Comparison
Co Diagnostics is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,280. Co Diagnostics holds roughly 155 in number of employees claiming about 7% of equities under Health Care industry.
Co Diagnostics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Co Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Co Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Co Diagnostics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Serbin Richard S few days ago Disposition of 48333 shares by Serbin Richard S of Co Diagnostics subject to Rule 16b-3 | ||
Dwight Egan over a month ago Acquisition by Dwight Egan of 275000 shares of Co Diagnostics subject to Rule 16b-3 | ||
Brown Brian Lee over two months ago Acquisition by Brown Brian Lee of 225000 shares of Co Diagnostics subject to Rule 16b-3 | ||
Murphy Ted over three months ago Acquisition by Murphy Ted of 30000 shares of Co Diagnostics subject to Rule 16b-3 | ||
Nelson James B over six months ago Acquisition by Nelson James B of 110000 shares of Co Diagnostics subject to Rule 16b-3 | ||
Brown Brian Lee over six months ago Disposition of 7869 shares by Brown Brian Lee of Co Diagnostics at 4.99 subject to Rule 16b-3 | ||
Dwight Egan over a year ago Acquisition by Dwight Egan of 150834 shares of Co Diagnostics subject to Rule 16b-3 | ||
Murphy Ted over a year ago Acquisition by Murphy Ted of 70000 shares of Co Diagnostics subject to Rule 16b-3 |
Co Diagnostics Notable Stakeholders
A Co Diagnostics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Co Diagnostics often face trade-offs trying to please all of them. Co Diagnostics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Co Diagnostics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dwight Egan | Chairman of the Board and Presidentident, CEO | Profile | |
Richard Abbott | President | Profile | |
Brian CPA | CFO Secretary | Profile | |
Reed Benson | CFO, Secretary | Profile | |
Brent Satterfield | Chief Science Officer, Director | Profile | |
Christopher Thurston | Chief Officer | Profile | |
Andrew Benson | Head Relations | Profile | |
Mayuranki Almaula | Senior Alliances | Profile | |
Dan CPA | Vice Accounting | Profile | |
Ivory Chang | Chief Officer | Profile | |
David Nielsen | Chief Officer | Profile | |
Cameron Gundry | Head LATAMEUR | Profile | |
Seth Egan | Chief Officer | Profile | |
Mark Poritz | Chief Officer | Profile |
About Co Diagnostics Management Performance
The success or failure of an entity such as Co Diagnostics often depends on how effective the management is. Co Diagnostics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CODX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CODX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.51) | (0.54) | |
Return On Capital Employed | (0.48) | (0.45) | |
Return On Assets | (0.37) | (0.39) | |
Return On Equity | (0.41) | (0.43) |
Please note, the imprecision that can be found in Co Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Co Diagnostics. Check Co Diagnostics' Beneish M Score to see the likelihood of Co Diagnostics' management manipulating its earnings.
Co Diagnostics Workforce Analysis
Traditionally, organizations such as Co Diagnostics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Co Diagnostics within its industry.Co Diagnostics Manpower Efficiency
Return on Co Diagnostics Manpower
Revenue Per Employee | 43.9K | |
Revenue Per Executive | 486.6K | |
Net Loss Per Employee | 228K | |
Net Loss Per Executive | 2.5M | |
Working Capital Per Employee | 363.8K | |
Working Capital Per Executive | 4M |
Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.